How Kress was paid
$65M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Jean-Paul KressPresident, Chief Executive Officer and Chairman | $344,615 | $400,000 | — | $64,013,465 | $251,425 | $18,064 | $65,027,569 |
| Robert AngFormer President and Chief Executive Officer | $515,026 | — | $184,250 | $1,176,895 | — | $1,488,224 | $3,364,395 |
| Sandesh MahatmeChief Financial Officer | $217,846 | $274,000 | $35,262,185 | $3,540,099 | $102,996 | $8,972 | $39,406,098 |
| Qing ZurawFormer Chief Development Officer | $243,385 | $100,000 | $2,230,250 | $8,570,852 | — | $692,706 | $11,837,193 |
What changed and why
- $65MCEO Jean-Paul Kress received total compensation of $65,027,569 for fiscal year 2025 following corporate transformation.
- The company announced the wind-down of prior operations and in-licensed telitacicept in 2025.
- 115%Corporate performance attainment for 2025 was determined by the board to be 115%.
- $3.4MFormer CEO Robert Ang received total compensation of $3,364,395 before resigning in June 2025.
Other Vor Biopharma proxy statements
- 2025 proxy statement
Robert Ang, M.B.B.S. paid $2.2M (-17% on the year).
Filed Aug 08, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.